RG
EPRX

Redmile Group’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Redmile Group’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.04M Sell
611,400
-88,600
-13% -$611K 0.27% 35
2026
Q1 		$5.07M Buy
+700,000
New +$5.63M 0.34% 30

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Redmile Group's EPRX Position: Q2 2026 in Review

Redmile Group reduced its Eupraxia Pharmaceuticals (EPRX) stake by 13% in Q2 2026, selling an estimated $611K and leaving 611,400 shares worth $4.04M. The position accounts for 0.27% of the portfolio, ranked #35.

Redmile Group first reported a position in EPRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.07M in Q1 2026. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Redmile Group held 611,400 shares of Eupraxia Pharmaceuticals worth $4.04M as of Q2 2026.
  • Redmile Group sold 88,600 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $611K.
  • Eupraxia Pharmaceuticals made up 0.27% of Redmile Group's portfolio in Q2 2026, its #35 holding.
  • Redmile Group first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Redmile Group's Eupraxia Pharmaceuticals position peaked at $5.07M in Q1 2026.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.